PMID- 35274130
OWN - NLM
STAT- MEDLINE
DCOM- 20220725
LR  - 20220920
IS  - 2047-2412 (Electronic)
IS  - 2047-2404 (Print)
IS  - 2047-2404 (Linking)
VI  - 23
IP  - 8
DP  - 2022 Jul 21
TI  - Effect of tafamidis on global longitudinal strain and myocardial work in 
      transthyretin cardiac amyloidosis.
PG  - 1029-1039
LID - 10.1093/ehjci/jeac049 [doi]
AB  - AIMS: In patients with transthyretin amyloid cardiomyopathy (ATTR-CM), the effect 
      of tafamidis on myocardial function using serial speckle tracking 
      echocardiography has not been reported. The purpose of this study was to describe 
      the natural history of myocardial function in untreated ATTR-CM and determine the 
      effect of tafamidis on myocardial functional parameters over 12 months of 
      treatment. METHODS AND RESULTS: A total of 45 subjects with ATTR-CM were 
      retrospectively studied: 23 treated with tafamidis and 22 untreated. 
      Two-dimensional speckle tracking echocardiography was analysed at baseline and 1 
      year. Serial longitudinal, circumferential, and radial strain, twist, torsion, 
      and myocardial work were measured. Over 1 year, absolute global longitudinal 
      strain (GLS) deteriorated more in the untreated group by a median of 1.1% 
      [inter-quartile range (IQR) 0.95] compared with 0.3% (IQR 1) in the tafamidis 
      group (P = 0.02). Myocardial work index and efficiency also deteriorated to a 
      greater degree: 142.5 mmHg% (IQR 197) and 4% (IQR 8), respectively, in the 
      untreated group compared with 61.5 mmHg% (IQR 210) and 1% (IQR 7) in the 
      tafamidis group (P = 0.04). There were no significant between group differences 
      in left ventricular ejection fraction (LVEF), tissue Doppler velocities, 
      circumferential or radial strain, LV twist or torsion at 1 year. The 
      stabilization effect of tafamidis on myocardial function at 1 year did not differ 
      according to baseline GLS, LVEF, or National Amyloidosis Centre disease stage. 
      CONCLUSIONS: In ATTR-CM, tafamidis resulted in a lesser deterioration in GLS, 
      myocardial work index, and efficiency over a 12-month period compared with a 
      cohort not treated with tafamidis.
CI  - (c) The Author(s) 2022. Published by Oxford University Press on behalf of the 
      European Society of Cardiology.
FAU - Giblin, Gerard T
AU  - Giblin GT
AUID- ORCID: 0000-0002-7452-5526
AD  - Cardiac Amyloidosis Program, Division of Cardiology, Department of Medicine, 
      Brigham and Women's Hospital and Harvard Medical School, 75 Francis Street, 
      Boston, MA 02115, USA.
FAU - Cuddy, Sarah A M
AU  - Cuddy SAM
AUID- ORCID: 0000-0002-2124-2151
AD  - Cardiac Amyloidosis Program, Division of Cardiology, Department of Medicine, 
      Brigham and Women's Hospital and Harvard Medical School, 75 Francis Street, 
      Boston, MA 02115, USA.
FAU - Gonzalez-Lopez, Esther
AU  - Gonzalez-Lopez E
AD  - Heart Failure and Inherited Cardiac Diseases Unit, Department of Cardiology, 
      Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain.
FAU - Sewell, Alanna
AU  - Sewell A
AD  - Cardiac Amyloidosis Program, Division of Cardiology, Department of Medicine, 
      Brigham and Women's Hospital and Harvard Medical School, 75 Francis Street, 
      Boston, MA 02115, USA.
FAU - Murphy, Amanda
AU  - Murphy A
AD  - Cardiac Amyloidosis Program, Division of Cardiology, Department of Medicine, 
      Brigham and Women's Hospital and Harvard Medical School, 75 Francis Street, 
      Boston, MA 02115, USA.
FAU - Dorbala, Sharmila
AU  - Dorbala S
AUID- ORCID: 0000-0003-1462-1185
AD  - Cardiac Amyloidosis Program, Division of Cardiology, Department of Medicine, 
      Brigham and Women's Hospital and Harvard Medical School, 75 Francis Street, 
      Boston, MA 02115, USA.
FAU - Falk, Rodney H
AU  - Falk RH
AUID- ORCID: 0000-0002-3329-2033
AD  - Cardiac Amyloidosis Program, Division of Cardiology, Department of Medicine, 
      Brigham and Women's Hospital and Harvard Medical School, 75 Francis Street, 
      Boston, MA 02115, USA.
LA  - eng
PT  - Journal Article
PL  - England
TA  - Eur Heart J Cardiovasc Imaging
JT  - European heart journal. Cardiovascular Imaging
JID - 101573788
RN  - 0 (Benzoxazoles)
RN  - 0 (Prealbumin)
RN  - 8FG9H9D31J (tafamidis)
SB  - IM
CIN - Eur Heart J Cardiovasc Imaging. 2022 May 02;:. PMID: 35511043
MH  - *Amyloidosis/diagnostic imaging/drug therapy
MH  - Benzoxazoles
MH  - Humans
MH  - Prealbumin
MH  - Retrospective Studies
MH  - Stroke Volume
MH  - *Ventricular Function, Left
PMC - PMC9303005
OTO - NOTNLM
OT  - myocardial work index
OT  - strain echocardiography
OT  - tafamidis
OT  - transthyretin amyloidosis
EDAT- 2022/03/12 06:00
MHDA- 2022/07/26 06:00
PMCR- 2022/03/11
CRDT- 2022/03/11 05:41
PHST- 2022/02/18 00:00 [received]
PHST- 2022/02/25 00:00 [accepted]
PHST- 2022/03/12 06:00 [pubmed]
PHST- 2022/07/26 06:00 [medline]
PHST- 2022/03/11 05:41 [entrez]
PHST- 2022/03/11 00:00 [pmc-release]
AID - 6546877 [pii]
AID - jeac049 [pii]
AID - 10.1093/ehjci/jeac049 [doi]
PST - ppublish
SO  - Eur Heart J Cardiovasc Imaging. 2022 Jul 21;23(8):1029-1039. doi: 
      10.1093/ehjci/jeac049.